{"url_path":"/sec/otlc/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-031124-index.html","accession_number":"0001493152-26-031124","cik":"0000908259","ticker":"OTLC","issuer_name":"Oncotelic Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-031124-index.html","primary_entity_key":"0000908259","primary_entity_name":"Oncotelic Therapeutics, Inc."},"word_count":87,"has_tables":true,"body_markdown":"**Item\n9.01**\n**Financial\nStatements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n \n**Incorporation\nby reference**\n\n \n \n \n \n \n\n10.1\n \n[Securities Purchase Agreement](ex10-1.htm)\n \nFiled\nherewith\n\n10.2\n \n[Convertible Promissory Note](ex10-2.htm)\n \nFiled\nherewith\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n \n \n\n \n\n-3-\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nOncotelic\nTherapeutics, Inc.\n\n \n \n \n\nDate:\nJune 29, 2026\n \n*/s/\nVuong Trieu*\n\n \nBy:\nVuong\nTrieu\n\n \n \nChief\nExecutive Officer\n\n \n\n-4-"}